IS2712B - Notkun týrósínkínasatálma til að meðhöndla sykursýki - Google Patents
Notkun týrósínkínasatálma til að meðhöndla sykursýkiInfo
- Publication number
- IS2712B IS2712B IS8139A IS8139A IS2712B IS 2712 B IS2712 B IS 2712B IS 8139 A IS8139 A IS 8139A IS 8139 A IS8139 A IS 8139A IS 2712 B IS2712 B IS 2712B
- Authority
- IS
- Iceland
- Prior art keywords
- tyrosine kinase
- kinase inhibitors
- diabetes
- treat diabetes
- type
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0312086A GB0312086D0 (en) | 2003-05-27 | 2003-05-27 | Organic compounds |
| GB0402682A GB0402682D0 (en) | 2004-02-06 | 2004-02-06 | Organic compounds |
| PCT/EP2004/005679 WO2004105763A2 (en) | 2003-05-27 | 2004-05-26 | Use of tyrosine kinase inhibitor to treat diabetes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IS8139A IS8139A (is) | 2005-11-22 |
| IS2712B true IS2712B (is) | 2011-01-15 |
Family
ID=33492240
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IS8139A IS2712B (is) | 2003-05-27 | 2005-11-22 | Notkun týrósínkínasatálma til að meðhöndla sykursýki |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US7875616B2 (is) |
| EP (1) | EP1631291B1 (is) |
| JP (1) | JP4776537B2 (is) |
| KR (1) | KR101102229B1 (is) |
| AT (1) | ATE439133T1 (is) |
| BR (1) | BRPI0410704A (is) |
| CA (1) | CA2526594C (is) |
| DE (1) | DE602004022540D1 (is) |
| DK (1) | DK1631291T3 (is) |
| ES (1) | ES2331800T3 (is) |
| HK (1) | HK1087638A1 (is) |
| IL (1) | IL171927A (is) |
| IS (1) | IS2712B (is) |
| MA (1) | MA27812A1 (is) |
| MX (1) | MXPA05012739A (is) |
| NO (1) | NO331715B1 (is) |
| NZ (1) | NZ543709A (is) |
| PL (1) | PL1631291T3 (is) |
| PT (1) | PT1631291E (is) |
| RU (1) | RU2365373C2 (is) |
| WO (1) | WO2004105763A2 (is) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1653934B1 (en) * | 2003-08-15 | 2008-05-14 | AB Science | Use of c-kit inhibitors for treating type ii diabetes |
| US20060094682A1 (en) * | 2004-10-29 | 2006-05-04 | Odyssey Thera, Inc. | Kinase inhibitors for the treatment of diabetes and obesity |
| WO2008001885A1 (fr) * | 2006-06-30 | 2008-01-03 | Kyowa Hakko Kirin Co., Ltd. | INHIBITEUR DE KINASE Abl |
| CA2848210A1 (en) * | 2011-09-15 | 2013-03-21 | Novartis Ag | Use of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one in the treatment of cancer in moderate hepatic impaired patients |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW225528B (is) * | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
| EP0773313B1 (de) * | 1995-10-11 | 2000-08-09 | ARTEVA TECHNOLOGIES S.à.r.l. | Schwerentflammbare Sicherheitsgurte enthaltend phosphor-modifizierte Polyesterfasern |
| CO4940418A1 (es) * | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
| GB9716557D0 (en) * | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
| DK1033364T3 (da) * | 1999-03-01 | 2005-06-06 | Pfizer Prod Inc | Cyanholdige oxamidsyrer og -derivater som thyroideareceptorligander |
| HUP0301865A3 (en) | 2000-02-15 | 2005-12-28 | Teva Pharma | A method for synthesizing leflunomide |
| US7087608B2 (en) * | 2000-03-03 | 2006-08-08 | Robert Charles Atkins | Use of PDGF receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy |
| MY128450A (en) * | 2000-05-24 | 2007-02-28 | Upjohn Co | 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives |
| JP2004518669A (ja) | 2000-12-20 | 2004-06-24 | スージェン・インコーポレーテッド | ４−アリール置換インドリノン |
| AU2002334355A1 (en) | 2001-09-06 | 2003-03-18 | Prochon Biotech Ltd. | Protein tyrosine kinase inhibitors |
| AUPS243002A0 (en) | 2002-05-20 | 2002-06-13 | Baker Medical Research Institute | Therapeutic target and uses thereof |
| DE10235227A1 (de) * | 2002-08-01 | 2004-02-19 | Johann Berger | Verfahren zur Herstellung eines gewebten Gurtbandes |
| AU2003259713A1 (en) | 2002-08-09 | 2004-02-25 | Theravance, Inc. | Oncokinase fusion polypeptides associated with hyperproliferative and related disorders, nucleic acids encoding the same and methods for detecting and identifying the same |
| WO2004043408A2 (en) | 2002-11-13 | 2004-05-27 | Genpath Pharmaceuticals, Incorporated | Gpc15: methods and compositions for treating cancer |
| DE10255360A1 (de) * | 2002-11-27 | 2004-06-17 | Johann Berger | Verfahren zur Herstellung eines gewebten Gurtbandes |
-
2004
- 2004-05-26 DE DE602004022540T patent/DE602004022540D1/de not_active Expired - Lifetime
- 2004-05-26 ES ES04739375T patent/ES2331800T3/es not_active Expired - Lifetime
- 2004-05-26 WO PCT/EP2004/005679 patent/WO2004105763A2/en active IP Right Grant
- 2004-05-26 EP EP04739375A patent/EP1631291B1/en not_active Expired - Lifetime
- 2004-05-26 PL PL04739375T patent/PL1631291T3/pl unknown
- 2004-05-26 KR KR1020057022515A patent/KR101102229B1/ko not_active IP Right Cessation
- 2004-05-26 US US10/556,984 patent/US7875616B2/en not_active Expired - Fee Related
- 2004-05-26 CA CA2526594A patent/CA2526594C/en not_active Expired - Fee Related
- 2004-05-26 MX MXPA05012739A patent/MXPA05012739A/es active IP Right Grant
- 2004-05-26 NZ NZ543709A patent/NZ543709A/xx not_active IP Right Cessation
- 2004-05-26 BR BRPI0410704-7A patent/BRPI0410704A/pt active Search and Examination
- 2004-05-26 AT AT04739375T patent/ATE439133T1/de active
- 2004-05-26 DK DK04739375T patent/DK1631291T3/da active
- 2004-05-26 PT PT04739375T patent/PT1631291E/pt unknown
- 2004-05-26 JP JP2006529925A patent/JP4776537B2/ja not_active Expired - Fee Related
- 2004-05-26 RU RU2005140516/15A patent/RU2365373C2/ru not_active IP Right Cessation
-
2005
- 2005-11-14 IL IL171927A patent/IL171927A/en not_active IP Right Cessation
- 2005-11-22 IS IS8139A patent/IS2712B/is unknown
- 2005-11-24 MA MA28624A patent/MA27812A1/fr unknown
- 2005-12-23 NO NO20056188A patent/NO331715B1/no not_active IP Right Cessation
-
2006
- 2006-07-17 HK HK06107985.6A patent/HK1087638A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| IL171927A (en) | 2011-10-31 |
| AU2004243491A1 (en) | 2004-12-09 |
| US7875616B2 (en) | 2011-01-25 |
| JP4776537B2 (ja) | 2011-09-21 |
| PT1631291E (pt) | 2009-10-28 |
| RU2365373C2 (ru) | 2009-08-27 |
| HK1087638A1 (en) | 2006-10-20 |
| MA27812A1 (fr) | 2006-03-01 |
| DK1631291T3 (da) | 2009-11-02 |
| DE602004022540D1 (de) | 2009-09-24 |
| NO20056188L (no) | 2005-12-23 |
| IS8139A (is) | 2005-11-22 |
| RU2005140516A (ru) | 2007-07-10 |
| KR20060021865A (ko) | 2006-03-08 |
| EP1631291B1 (en) | 2009-08-12 |
| IL171927A0 (en) | 2006-04-10 |
| NZ543709A (en) | 2009-04-30 |
| CA2526594A1 (en) | 2004-12-09 |
| US20070072932A1 (en) | 2007-03-29 |
| CA2526594C (en) | 2011-11-08 |
| EP1631291A2 (en) | 2006-03-08 |
| JP2006528225A (ja) | 2006-12-14 |
| KR101102229B1 (ko) | 2012-01-05 |
| ES2331800T3 (es) | 2010-01-15 |
| PL1631291T3 (pl) | 2010-04-30 |
| MXPA05012739A (es) | 2006-05-17 |
| WO2004105763A3 (en) | 2005-06-02 |
| BRPI0410704A (pt) | 2006-06-13 |
| NO331715B1 (no) | 2012-03-05 |
| ATE439133T1 (de) | 2009-08-15 |
| WO2004105763A2 (en) | 2004-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE321556T1 (de) | Behandlung gastrointestinaler stroma-tumoren | |
| NO20070453L (no) | Kondenserte heterocykliske kinase inhibitorer | |
| ATE517896T1 (de) | P38-kinase-inhibitoren | |
| PT998473E (pt) | Modificacao da forma de cristal de um derivado de n-fenil-2-pirimidinoamina processos para a sua preparacao e sua utilizacao | |
| DK1585743T3 (da) | 2-(H-indazol-6-ylamino)-benzamid forbindelser som protein kinase inhibitorer, nyttige til behandling opthalmiske sygdomme | |
| BR0312873A (pt) | 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il) pirimidin-2-ilamino)fenil] benzamida para tratamento de doenças associadas com ret cinase mutante | |
| ES2421587T3 (es) | Uso de derivados de pirimidilaminobenzamida para el tratamiento de mastocitosis sistémica | |
| IS2712B (is) | Notkun týrósínkínasatálma til að meðhöndla sykursýki | |
| ATE359283T1 (de) | Substituierte pyrazinonverbindungen zur behandlung von entzündungen | |
| DE602007011756D1 (de) | Verwendung eines p38-kinasehemmers zur behandlung von psychiatrischen erkrankungen | |
| ATE399555T1 (de) | Behandlung der rheumatoiden arthritis mit imitanib | |
| BR0316126A (pt) | Combinação de compostos para o tratamento de leucemia linfocìtica crÈnica | |
| BR0312242A (pt) | 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il) pirimidin-2-ilamino)fenil]-benzamida para o tratamento da fibrose pulmonar | |
| TNSN05304A1 (en) | Use of tyrosine kinase inhibitor to treat diabetes | |
| ATE492277T1 (de) | Verwendung von 4-(4-methylpiperazin-1-ylmethyl)-n-4-methyl-3-( -(pyridin-3-yl)pyrimidin-2- ylamino)phenyl-benzamid zur hemmung des tyrosinkinaserezeptors c-fms | |
| WO2006012958A3 (en) | Combination comprising a bcrp inhibitor and 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide | |
| DE60305460D1 (de) | Verwendung von 4-(4-methylpiperazin-1-ylmethyl)-n 4-methyl-3-(4-pyridin-3-yl) pyrimidin-2-ylamino) phenyl benzamid zur behandlung von seminomen | |
| WO2004026930A3 (en) | The method for reducing inflammation using sti-571 or its salt | |
| UY28498A1 (es) | Modificación de cristal de un derivado de n-fenil-2-pirimidinamina, procesos para su fabricación y su uso. |